<?xml version="1.0" encoding="UTF-8"?>
<ref id="B29-viruses-12-00838">
 <label>29.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Eron</surname>
    <given-names>J.J.</given-names>
   </name>
   <name>
    <surname>Clotet</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Durant</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Katlama</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Kumar</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Lazzarin</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Poizot-Martin</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Richmond</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Soriano</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Ait-Khaled</surname>
    <given-names>M.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study</article-title>
  <source>J. Infect. Dis.</source>
  <year>2012</year>
  <volume>207</volume>
  <fpage>740</fpage>
  <lpage>748</lpage>
  <pub-id pub-id-type="doi">10.1093/infdis/jis750</pub-id>
  <?supplied-pmid 23225901?>
  <pub-id pub-id-type="pmid">23225901</pub-id>
 </element-citation>
</ref>
